A comprehensive view of Inflammations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca signs US$402.0M global licensing agreement with C4XD for its NRF2 activator program; AstraZeneca to oversee development, commercialization of oral treatment for chronic obstructive pulmonary disease, other inflammatory and respiratory diseases

Scientists develop plant-based anti-inflammatory, antioxidant electrospun nanofibers for wound healing efficiency; nanofibers are made with polycaprolactone, gelatin, are loaded with phytochemical quercetin, have bactericidal activity: SRM Institute

Executive Perspective: Pfizer CEO says 2023 will be a pivotal year for the company with up to 10 new drug launches; Pfizer planning to launch five new vaccines, new oncology and immuno-inflammation drugs in the next year

Amgen opens new 245,000 square-foot, nine-story R&D facility in San Francisco, California, with staff of 650; new facility to focus on discovering cancer, inflammatory disease, cardiometabolic disorder therapies

Cell therapy developed at Cedars-Sinai delays disease progression in Duchenne muscular dystrophy patients who have few treatment options; treatment uses cardiosphere heart muscle cells to improve heart, skeletal muscle function, blunt inflammation

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count